Skip to content
value.today

Align Technology, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 2.6% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $10.7 B means free cash flow growing 7.0% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew 2.6% a year over the last three years.

Cash-flow value of the shares
$7.7 B
-27% against the market value
Value of the whole business
$7.7 B
before net debt
Value from after year 10
49%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-2.39%0.11%2.61%5.11%7.61%
8.15%-33%-19%-2%+19%+45%
9.15%-42%-31%-16%+1%+22%
10.15%-49%-39%-27%-13%+4%
11.15%-54%-46%-36%-23%-9%
12.15%-59%-51%-42%-32%-19%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Medical Devices: $8.7 B to $15.5 B, median $9.8 BPrice to salesPrice to sales of Medical Devices: $4.9 B to $13.7 B, median $9.3 BPrice to bookPrice to book of Medical Devices: $5.7 B to $20.8 B, median $10.4 BCash-flow value$0 M$5.6 B$11.2 B$16.8 B$22.4 BMarket value $10.7 B

Your own DCF model

A full discounted-cash-flow model of Align Technology, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Devices

Multiples of its companies with a market value at most 60 days old, times Align Technology, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Align Technology, Inc.Applied toValue (25th to 75th)Companies
P/E21.2× / 24.0× / 37.7×21.7×net income $410 M$8.7 B to $15.5 B18
Price to sales1.2× / 2.3× / 3.4×2.6×revenue $4.0 B$4.9 B to $13.7 B36
Price to book1.4× / 2.6× / 5.1×2.6×book equity $4.0 B$5.7 B to $20.8 B36

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Align Technology, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

25.8×

Now below its median of 30.3×, in the bottom quarter of its range; range 20.6× to 95.2× over 30 months.

0×24×48×71×95×2020202120222023202420252026P/E 26×Median 30×

Price to sales

2.6×

Now below its median of 3.2×, in the bottom quarter of its range; range 2.4× to 17.5× over 30 months.

0×4×9×13×18×2020202120222023202420252026Price to sales 3×Median 3×

Price to book

2.6×

Now below its median of 3.4×, in the bottom quarter of its range; range 2.4× to 31.3× over 30 months.

0×8×16×23×31×2020202120222023202420252026Price to book 3×Median 3×

as of Oct 22, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 22, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$4.0 B$410 M$593 M$102 M$491 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$4.0 B$421 M$738 M$116 M$623 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$3.9 B$445 M$786 M$178 M$608 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$3.7 B$362 M$569 M$292 M$277 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$4.0 B$772 M$1.2 B$401 M$771 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$2.5 B$1.8 B$662 M$155 M$507 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $10.7 B on Oct 22, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.